
RSV prophylaxis: Palivizumab, nirsevimab, and more
Respiratory syncytial virus (RSV) illness is an extremely common cause of hospitalization in children in the United States and globally. An estimated 90% of children will be infected by 2 years of age, leading to over 3 million hospitalizations annually …